News
LNSR
4.990
+1.63%
0.080
Weekly Report: what happened at LNSR last week (1109-1113)?
Weekly Report · 2d ago
LENSAR’s Recurring Revenue and Profitability Improve, but Price Target Cut to $9
TipRanks · 11/11 10:26
LENSAR Records Wider Q3 Loss Of $4 Mln; Shares Drop Over 15%
NASDAQ · 11/11 09:43
These healthcare stocks have tumbled in 2026, yet Quant ratings stay positive
Seeking Alpha · 11/10 17:38
Lensar reports Q3 EPS (38c), consensus (14c)
TipRanks · 11/10 16:50
Lensar Is Maintained at Buy by BTIG
Dow Jones · 11/10 15:56
Lensar Price Target Cut to $9.00/Share From $10.00 by BTIG
Dow Jones · 11/10 15:56
BTIG Maintains Buy on LENSAR, Lowers Price Target to $9
Benzinga · 11/10 15:46
LENSAR Q3 2026 Earnings Call Transcript
Benzinga · 11/10 14:23
LENSAR, Inc. Q3 Loss Increases
NASDAQ · 11/10 12:29
*Lensar 3Q Loss/Shr 38c >LNSR
Dow Jones · 11/10 12:00
Press Release: LENSAR(R) Reports Third Quarter 2026 Financial Results and Provides Business Update
Dow Jones · 11/10 12:00
*Lensar 3Q Loss $4.72M >LNSR
Dow Jones · 11/10 12:00
*Lensar 3Q Rev $14.1M >LNSR
Dow Jones · 11/10 12:00
Weekly Report: what happened at LNSR last week (1102-1106)?
Weekly Report · 11/09 10:04
Weekly Report: what happened at LNSR last week (1026-1030)?
Weekly Report · 11/02 10:04
Weekly Report: what happened at LNSR last week (1019-1023)?
Weekly Report · 10/26 10:04
Weekly Report: what happened at LNSR last week (1012-1016)?
Weekly Report · 10/19 10:04
Weekly Report: what happened at LNSR last week (1005-1009)?
Weekly Report · 10/12 10:08
Cedar Grove Capital Q3 2026 Portfolio Update
Seeking Alpha · 10/07 19:48
More
Webull provides a variety of real-time LNSR stock news. You can receive the latest news about Lensar Inc through multiple platforms. This information may help you make smarter investment decisions.
About LNSR
LENSAR, Inc. is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. The Company's product portfolio includes the LENSAR Laser System and the ALLY Robotic Cataract Laser System and their associated consumable components. It has developed its ALLY System as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating artificial intelligence into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing its advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite. ALLY allows the surgeon to switch between cataract laser and the surgeon’s existing phacoemulsification device without moving patients from room-to-room. ALLY includes its proprietary Streamline software technology.